Therapeutic Asset Ratings

3,272 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Veliparib Head And Neck Cancer	National Cancer Institute (NCI)	P1	CC (43)
Veliparib Testicular Cancer	National Cancer Institute (NCI)	P1	CC (43)
Venetoclax Diffuse Large B-Cell Lymphoma Of The Central Nervous System	National Cancer Institute (NCI)	P1	CC (43)
(+)-Vincristine T-Cell/Histiocyte Rich Large B Cell Lymphoma	National Cancer Institute (NCI)	P1	CC (43)
Vincristine Sulfate Adult T-Cell Leukemia/Lymphoma	National Cancer Institute (NCI)	P1	CC (43)
Vincristine Sulfate Human T-Lymphotropic Virus 1 Infectious Disease	National Cancer Institute (NCI)	P1	CC (43)
Vorinostat Anaplastic Astrocytoma	National Cancer Institute (NCI)	P1	CC (43)
Vorinostat Anaplastic Oligodendroglioma	National Cancer Institute (NCI)	P1	CC (43)
Vorinostat Undifferentiated Carcinoma Of Nasopharynx	National Cancer Institute (NCI)	P1	CC (43)
(Z)-Endoxifen Breast Carcinoma In Situ	National Cancer Institute (NCI)	P1	CC (43)
(Z)-Endoxifen Lobular Breast Carcinoma In Situ	National Cancer Institute (NCI)	P1	CC (43)
Ziv-Aflibercept Renal Cell Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Azacytidine Non-Small Cell Lung Carcinoma	National Cancer Institute (NCI)	P1/2	CC (43)
Entinostat Nonpapillary Renal Cell Carcinoma	National Cancer Institute (NCI)	P1/2	CC (43)
Entinostat Renal Carcinoma	National Cancer Institute (NCI)	P1/2	CC (43)
Entinostat Penile Cancer	National Cancer Institute (NCI)	P1/2	CC (43)
gad20-209-fsp, rp2d Colorectal Carcinoma	National Cancer Institute (NCI)	P1/2	CC (43)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Epithelial Neoplasm	National Cancer Institute (NCI)	P1/2	CC (43)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Prostate Neoplasm	National Cancer Institute (NCI)	P1/2	CC (43)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Vaginal Cancer	National Cancer Institute (NCI)	P1/2	CC (43)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Vulva Cancer	National Cancer Institute (NCI)	P1/2	CC (43)
Mirdametinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P1/2	CC (43)
Mva-209-Fsp, Rp2D Colorectal Carcinoma	National Cancer Institute (NCI)	P1/2	CC (43)
pds01adc Anal Carcinoma	National Cancer Institute (NCI)	P1/2	CC (43)
Prgn-2009 Anal Carcinoma	National Cancer Institute (NCI)	P1/2	CC (43)

Showing 3051 to 3075 of 3,272 assets

PreviousPage 123 of 131Next